# Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease

> **NCT06272630** · PHASE4 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 263 (actual)

## Conditions studied

- Chronic Liver Disease

## Interventions

- **DRUG:** DWJ1464
- **DRUG:** Placebo of DWJ1464

## Key facts

- **NCT ID:** NCT06272630
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-06
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-03-29
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06272630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06272630, "Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06272630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*